

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)

6 July 2017

Cleansing Notice

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) announced that it has issued 2,631,268 of its NASDAQ listed American Depositary Shares (“ADSs”) at a purchase price per ADS of US\$1.90 issue and unregistered warrants to purchase up to 1,973,451 of its ADSs to accredited investors. The warrants have an exercise price of US\$2.50 per ADS, are exercisable immediately and will expire 5.5 years from the date of issuance.

With respect to the shares the subject of this issuance as further detailed in the Appendix 3B lodged on 4 July 2017, the Company gives notice under section 708A(5)(e) of the *Corporations Act 2001*(Cth) (the "Corporations Act") that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
2. as at the date of this notice the Company has complied with:
 - (a) the provisions of Chapter 2M *Corporations Act* as they apply to the Company; and
 - (b) section 674 *Corporations Act*; and
3. As at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the *Corporations Act*) which is required to be disclosed by the Company.

Yours faithfully
Prima BioMed Ltd



Deanne Miller
Company Secretary

For personal use only